2711 days ago
Amryt Pharma (AMYT) has announced that it has secured a €20m debt facility from the European Investment Bank on, what broker Stifel says, are very attractive commercial terms. Stifel says that the facility will not only extend the company's funding until well into 2019, but also provide funding for development of acromegaly product AP102 and potential launch funding for Episalvan in partial thickness wounds. Stifel concludes that the shares are a buy at 14p with a price target of 49p. Yes indeed. Since we own the shares I thought we'd share the note with you.
